Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xeris Biopharma HoldingsFRA:2B30 -0.56%73 Cash Ratio is 0.64 as of Jun. 2026, which is 66% below its 10-year median of 1.86. GuruFocus rates FRA:2B30 with a GF Score™ of 73/100 and a GF Value™ of €4.66 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 967 Drug Manufacturers companies, Xeris Biopharma Holdings ranks better than 53.05% on this metric.
Xeris Biopharma Holdings has a Cash Ratio of 0.64. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Xeris Biopharma Holdings's Cash Ratio or its related term are showing as below:
FRA:2B30'
s Cash Ratio Range Over the Past 10 Years
Min: 0.61 Med: 1.86 Max: 15.97
Current: 0.64
During the past 10 years, Xeris Biopharma Holdings's highest Cash Ratio was 15.97. The lowest was 0.61. And the median was 1.86.
FRA:2B30's Cash Ratio is ranked better than 53.05% of 967
companies
in the Drug Manufacturers industry
Industry Median: 0.57
vs FRA:2B30: 0.64
Xeris Biopharma Holdings (FRA:2B30) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Xeris Biopharma Holdings Cash Ratio Related Terms
Xeris Biopharma Holdings Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2B30 vs PAHC, ANIP, HROW: Cash Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Xeris Biopharma Holdings's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xeris Biopharma Holdings Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xeris Biopharma Holdings's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Xeris Biopharma Holdings's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xeris Biopharma Holdings (FRA:2B30) has a Cash Ratio of 0.64 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Xeris Biopharma Holdings and its competitors. This is 66% below median its historical median of 1.86. Over the past decade, Xeris Biopharma Holdings' Cash Ratio has ranged from 0.61 to 15.97. According to the industry distribution chart, Xeris Biopharma Holdings ranks #454 out of 967 companies in the Drug Manufacturers industry, placing it in the top 46.9%.
Is Xeris Biopharma Holdings' Cash Ratio too high?
Xeris Biopharma Holdings' current Cash Ratio of 0.64 is 66% below median its 10-year median of 1.86. Over the past 10 years, this metric has ranged from a low of 0.61 to a high of 15.97. The Drug Manufacturers industry median Cash Ratio is 0.57. Xeris Biopharma Holdings' value of 0.64 is 12.3% above this industry median. Based on the distribution chart, Xeris Biopharma Holdings ranks #454 out of 967 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Xeris Biopharma Holdings has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xeris Biopharma Holdings' Cash Ratio compare to PAHC and ANIP?
According to the Drug Manufacturers industry distribution chart, Xeris Biopharma Holdings ranks #454 out of 967 companies for Cash Ratio. This puts Xeris Biopharma Holdings in the upper half of its industry. The industry median Cash Ratio is 0.57. Xeris Biopharma Holdings' value of 0.64 is 12.3% above this benchmark. Historically, Xeris Biopharma Holdings' own Cash Ratio has ranged from 0.61 to 15.97 over the past decade. While the company's 10-year median is 1.86 vs. the industry median of 0.57, Xeris Biopharma Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.57, based on 967 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xeris Biopharma Holdings's current Cash Ratio of 0.64 is 12.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Xeris Biopharma Holdings and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xeris Biopharma Holdings's current Cash Ratio is 0.64, which is 66% below median its own 10-year median of 1.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeris Biopharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xeris Biopharma Holdings (FRA:2B30) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.66, compared to a current price of €7.16 — trading 53.7% above its estimated fair value. The current Cash Ratio is 0.64, which is 66% below median its 10-year median of 1.86 and 12.3% above the Drug Manufacturers industry median of 0.57. Xeris Biopharma Holdings' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Xeris Biopharma Holdings (FRA:2B30), the current Cash Ratio is 0.64 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xeris Biopharma Holdings (FRA:2B30) Overvalued in 2026?
Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued.
The current stock price of €7.16 is trading 53.7% above its estimated GF Value™ of €4.66.
GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.
Key valuation signals for FRA:2B30:
Cash Ratio: 0.64 (66% below median its 10-year median of 1.86)
GF Value™: €4.66 vs. price of €7.16 (53.7% above fair value)
Industry Position: 12.3% above the Drug Manufacturers median (#454 of 967)
No single metric tells the full story. See the FRA:2B30 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
73GF Score
Get the complete analysis for FRA:2B30
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2B30 has been successfully added to your 
